NICE Should Ape Swiss HTA, Says Roche CEO
This article was originally published in Scrip
Executive Summary
The chief executive of the world's biggest maker of cancer drugs believes the drug approval process used by the UK's National Institute of Health and Care Excellence's needs revamping and that the country should look to Switzerland for a model to emulate.